Clinical efficacy of Yinhua Miyanling tablet in the treatment of uncomplicated urinary tract infections: A systematic review and meta-analysis
Abstract
Background: Although Yinhua Miyanling tablet has demonstrated promising efficacy in managing uncomplicated urinary tract infections (UTIs), robust clinical evidence from large-scale studies remains scarce. This systematic review aims to comprehensively evaluate the therapeutic effectiveness and safety profile of Yinhua Miyanling tablet in the treatment of uncomplicated UTIs, providing an evidence-based assessment for clinical practice.
Methods: A comprehensive computerized search was conducted across multiple databases, including China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Data, Chinese Biomedical Literature Database, Big Medical Knowledge Base, Medline, PubMed, Embase, Cochrane Library, and Web of Science. The search period spanned from the inception of each database to October 2023, aiming to identify randomized controlled trials (RCTs) investigating the efficacy of Yinhua Miyanling tablets in treating uncomplicated UTIs. The selected studies were subjected to meta-analysis using RevMan 5.3 software (The Cochrane Collaboration, London, United Kingdom). The methodological quality of the included literature was assessed using the Cochrane Risk of Bias Tool (version 5.1.0; The Cochrane Collaboration, London, United Kingdom) and the modified Jadad scale. Additionally, the GRADE system was employed to evaluate the overall quality of evidence.
Results: A total of 14 RCTs, involving 1773 patients, were included in the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,773 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.